logo
ResearchBunny Logo
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages

Medicine and Health

Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages

M. Chernychev, M. Sakharkar, et al.

This groundbreaking study reveals how vaccination of individuals previously infected with SARS-CoV-2 leads to intense and diverse antibody responses. Researchers isolated 459 spike-specific monoclonal antibodies, demonstrating their neutralizing ability against various viral variants, proving the efficacy of mRNA vaccines in enhancing immune response among convalescent individuals. Conducted by Mark Chernychev and colleagues.

00:00
00:00
Playback language: English
Abstract
Vaccination of SARS-CoV-2 convalescent individuals generates broad and potent antibody responses. This study isolated 459 spike-specific monoclonal antibodies (mAbs) from two individuals previously infected with SARS-CoV-2 and later boosted with mRNA-1273. The mAbs demonstrated a broad range of immunoglobulin heavy chain (IGH) V genes and neutralizing activity against various SARS-CoV-2 variants. Longitudinal analysis revealed extensive evolution of spike-binding antibodies from acute infection to vaccination five months later, highlighting the efficient recall of affinity-matured memory B cells by vaccination, leading to potent antibody responses in convalescent individuals.
Publisher
Nature Communications
Published On
Apr 19, 2023
Authors
Mark Chernychev, Mrunal Sakharkar, Ruth I. Connor, Haley L. Dugan, Daniel J. Sheward, C. G. Rappazzo, Aron Ståhlmarck, Mattias N. E. Forsell, Peter F. Wright, Martin Corcoran, Ben Murrell, Laura M. Walker, Gunilla B. Karlsson Hedestam
Tags
SARS-CoV-2
vaccination
antibody responses
spike-specific monoclonal antibodies
neutralizing activity
memory B cells
mRNA-1273

Related Publications

Explore these studies to deepen your understanding of the subject.

Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2
Medicine and Health

Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2

L. Wu, Q. Chen, et al.

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
Medicine and Health

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

A. L. Koen, A. Izu, et al.

Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)
Medicine and Health

Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)

A. J. M. Aabakke, T. G. Petersen, et al.

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
Medicine and Health

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J. Logue, R. M. Johnson, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny